• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Neurodegenerative Diseases.

  • ID: 2359099
  • October 2012
  • Region: Global
  • 117 Pages
  • Future Science Ltd

Guest edited by Gregory Cuny (University of Houston, TX, USA) in September 2012, Future Medicinal Chemistry published its special focus issue on neurodegenerative disease.

This special focus issue provides an overview of current themes and significant advances in the identification and modulation of molecular targets, pathways and aggregation in both chronic and acute neurodegenerative diseases.

The issue comprises special reports, perspectives and review articles from some of the leading laboratories in the field. Highlights include the perspective by David Schubert and Pamela Maher of the Salk Institute for Biological Studies (CA, USA) that considers a different approach to drug discovery in this disease area, highlighting the fact that there are currently “no drugs that halt the progression of any age-associated neurodegenerative disease.”

An ‘Ask the Experts’ feature resulting from conversations with eminent researchers in the field covers topical and pressing issues including bottlenecks in the development of effective treatments for neurodegenerative diseases, the impact of stem cells on this research area and future directions of the field.

The Guest Editor explains that: “One goal of this special issue is to encourage the neuroscience research community to challenge current therapeutic strategies for neurodegenerative diseases. These formidable conditions that have been resistant to disease modifying therapies, despite significant effort, necessitate exploration of new and diverse approaches.”

Note: Product cover images may vary from those shown


Neurodegenerative diseases: challenges and opportunities
Gregory D Cuny


Modeling neurodegenerative diseases using stem cells: is it accelerating drug discovery?
Allison D Ebert

Targeting the cellular prion protein to treat neurodegeneration
Emiliano Biasini, David A Harris


News & Analysis

Ask the Experts: The future of neurodegenerative diseases: emerging targets, treatments and technologies
John Voss, Allison Ebert, Michael Wolfe, Craig Lindsley, Mark Cookson, Rashid Deane


Small-molecule Klotho enhancers as novel treatment of neurodegeneration
Carmela R Abraham, CiDi Chen, Gregory D Cuny, Marcie A Glicksman, Ella Zeldich


An alternative approach to drug discovery for Alzheimer’s disease dementia
David Schubert, Pamela Maher

Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases
Chien-Liang Glenn Lin, Qiongman Kong, Gregory D Cuny, Marcie A Glicksman


Current understanding of LRRK2 in Parkinson’s disease: biochemical and structural features and inhibitor design
Soumya Ray, Min Liu

Modulating macroautophagy: a neuronal perspective
Christopher W Johnson, Thomas J Melia, Ai Yamamoto

Therapeutic strategies for the treatment of spinal muscular atrophy
Jonathan J Cherry, Elliot J Androphy
Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease
Laurent Calcul, Bo Zhang, Umesh K Jinwal, Chad A Dickey, Bill J Baker



Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S